Tag: retinal vein occlusion treatment market

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What is the Anticipated CAGR of the Retinal Vein Occlusion Treatment Market, and What Factors Will Drive It?

The market for retinal vein occlusion therapy has experienced robust expansion in the past few years. The market size is projected to increase from a value of $2.26 billion in 2024 to $2.42 billion in 2025, with a compound annual growth rate (CAGR) of 6.9%. This significant growth during the historic period can be credited to the adoption of combination treatments that aim at various aspects of disease pathology. Also, factors such as the rising incidence of diabetes and hypertension, improved access to healthcare and specialized care for the retina, clinical trial results highlighting the effectiveness of novel treatment methods, and the progression of anti-VEGF treatments have contributed substantially.

The market for retinal vein occlusion treatment is anticipated to witness substantial growth in the upcoming years, expanding to a size of$3.16 billion in 2029 with a compound annual growth rate (CAGR) of 6.9%. This positive expansion during the prediction period can be credited to factors such as the cost-effectiveness and widespread reimbursement policies, the inclination of patients towards non-invasive treatments options, rising global expenditure on healthcare, a swelling aging demographic, and the introduction of novel drugs and therapies. Significant trends set to mark the forecast period include the progression in gene therapy, the employment of nanotechnology in drug delivery, the use of artificial intelligence (AI) in diagnostic processes, telemedicine and remote healthcare monitoring, along with the emergence of patient-focused technologies.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18453&type=smp

What External and Internal Drivers Are Contributing to the Growth of theRetinal Vein Occlusion Treatment Market?

An upsurge in eye-related conditions is expected to fuel growth in the retinal vein occlusion treatment market. Such eye conditions encompass a spectrum of disorders or diseases, interfering with vision or the eye’s overall wellbeing. These can vary from trivial infections or irritations to severe cases like diabetic retinopathy, macular degeneration, glaucoma, and cataracts. Elements like increasing rates of diabetes and hypertension along with ageing populations contribute to the rising occurrences of these eye conditions. The primary goal of the treatment for retinal vein occlusion is to reinstate blood flow, manage complications tied to the eye conditions and reduce inflammation, thus preventing vision loss. For example, per the Centers for Disease Control and Prevention, a service organization in the United States driven by science and data for public health protection, over 3.4 million US citizens aged 40 years and above were suffering from visual impairment or blindness in January 2024. This figure is pegged to double by 2030. As such, the retinal vein occlusion treatment market is experiencing growth driven by the escalating prevalence of eye conditions.

What Segment Types Define the Retinal Vein Occlusion Treatment Market Structure?

The retinal vein occlusion treatmentmarket covered in this report is segmented –

1) By Disease Type: Central Retinal Vein Occlusion (CRVO); Branch Retinal Vein Occlusion (BRVO)

2) By Diagnosis: Optical Coherence Tomography; Fundoscopic Examination; Fluorescein Angiography

3) By Treatment: Anti-Vascular Endothelial Growth Factor (Anti-VEGF); Corticosteroid Drugs; Other Treatments

4) By End-User: Hospital And Clinics; Research And Academics; Other End-Users

Subsegments:

1) By Central Retinal Vein Occlusion (CRVO): Non-Ischemic CRVO; Ischemic CRVO

2) By Branch Retinal Vein Occlusion (BRVO): Non-Ischemic BRVO; Ischemic BRVO

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=18453&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Retinal Vein Occlusion Treatment Market?

North America was the largest region in the retinal vein occlusion treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the retinal vein occlusion treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Long-Term Trends Are Transforming the Competitive Landscape of the Retinal Vein Occlusion Treatment Market?

Leading businesses in the retinal vein occlusion treatment sector are concentrating on creating new products like interchangeable biosimilars to expand treatment alternatives and increase accessibility for patients. Interchangeable biosimilars are biologic drugs that closely resemble an existing reference biologic and can effectively manage inflammation and fluid leakage. For example, in May 2024, the US Food and Drug Administration gave approval to Biocon Biologics Limited, a biosimilar manufacturer from India, for the production of Yesafili (aflibercept-jbvf), an interchangeable biosimilar to EYLEA (aflibercept). This product acts as a vascular endothelial growth factor (VEGF) inhibitor, treating various eye-related conditions such as neovascular age-related macular degeneration (wet AMD), macular edema following retinal vein occlusion (either branch RVO or central RVO), diabetic macular edema (DME), and myopic choroidal neovascularization (myopic CNV).

View the full report here:

https://www.thebusinessresearchcompany.com/report/retinal-vein-occlusion-treatment-global-market-report

What Is the Definition of the Retinal Vein Occlusion Treatment Market?

Retinal vein occlusion (RVO) treatment involves various strategies aimed at managing complications caused by blocked blood vessels in the retina. These treatments typically focus on reducing swelling (edema) and preventing further vision loss.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18453

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#How Fast Is The Retinal Vein Occlusion Treatment Market Expected to Grow Between 2025 And 2029?#_x000D_

Over the past few years, the retinal vein occlusion treatment market has experienced robust growth. The market value is predicted to surge from $2.26 billion in 2024 to $2.43 billion in 2025, marking a compound annual growth rate (CAGR) of 7.3%. The growth witnessed in previous times can be associated with the increased adoption of combined treatments addressing the various aspects of disease pathophysiology. It’s further propelled by the rising prevalence of diseases like diabetes and hypertension, improved accessibility to healthcare services, and specialized retinal care, evidence of effectiveness of novel treatment methods through clinical trials, and the evolution of anti-VEGF therapies._x000D_

_x000D_

#What Growth Rate Is Anticipated for the Retinal Vein Occlusion Treatment Market in the Coming Years?#_x000D_

Expectations are high for robust expansion in the retinal vein occlusion treatment market in the coming years. Forecasts predict it will swell to $3.18 billion by 2029, driving forward with a compound annual growth rate (CAGR) of 7.0%. Factors propelling this growth over the predicted period include the affordability and reimbursement policies, a global increase in healthcare spending, the preference of patients for non-intensive treatments, the rapid aging of the global population, and advancements in drug and therapy development. Upcoming trends for the forecast period include progress in gene therapy, nanotechnology application for drug delivery, artificial intelligence (AI) usage in diagnostics, the rise of telemedicine and remote patient monitoring, and the emergence of patient-focused technologies._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=18453&type=smp_x000D_

_x000D_

#Who Are the Leading Companies in the Retinal Vein Occlusion Treatment Market?#_x000D_

Major companies operating in the retinal vein occlusion treatment market are Roche Holding AG, Bayer AG, Novartis International AG, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Santen Pharmaceutical Co. Ltd., Chengdu Kanghong Pharmaceutical Group Co. Ltd., Spark Therapeutics Inc., Genentech Inc., Apellis Pharmaceuticals Inc., Alimera Sciences Inc., Ocular Therapeutix Inc., EyePoint Pharmaceuticals Inc., Aerpio Pharmaceuticals Inc., REGENXBIO Inc., Stealth BioTherapeutics Corp., Adverum Biotechnologies Inc., Graybug Vision Inc., Oxurion NV, PanOptica Inc., Clearside Biomedical Inc._x000D_

_x000D_

#What Are the Key Drivers of the Retinal Vein Occlusion Treatment Market?#_x000D_

The rising occurrence of eye-related disorders is anticipated to fuel the growth of the retinal vein occlusion treatment market. Such eye disorders encompass a vast array of issues from minor disturbances and infections to grave illnesses such as glaucoma, cataracts, macular atrophy, and diabetic retinopathy. The escalation in these eye conditions can be tied to factors like the aging population, and the rising incidents of diabetes and hypertension. The goal of retinal vein occlusion treatment is to restore blood circulation, decrease inflammation, prevent loss of sight, and handle any complications connected to this eye ailment. For example, the Centers for Disease Control and Prevention recorded that over 3.4 million Americans who are 40 years old and above were either blind or had visual impairment in January 2024, with predictions that this figure will double by 2030. Hence, the rising incidence of eye-related disorders bolsters the growth of the retinal vein occlusion treatment market._x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=18453&type=smp_x000D_

_x000D_

#What Are the Key Market Segments in the Retinal Vein Occlusion Treatment Industry?#_x000D_

The retinal vein occlusion treatment market covered in this report is segmented –_x000D_

_x000D_

1) By Disease Type: Central Retinal Vein Occlusion (CRVO), Branch Retinal Vein Occlusion (BRVO)_x000D_

2) By Diagnosis: Optical Coherence Tomography, Fundoscopic Examination, Fluorescein Angiography_x000D_

3) By Treatment: Anti-Vascular Endothelial Growth Factor (Anti-VEGF), Corticosteroid Drugs, Other Treatments_x000D_

4) By End-User: Hospital And Clinics, Research And Academics, Other End-Users_x000D_

_x000D_

Subsegments:_x000D_

1) By Central Retinal Vein Occlusion (CRVO): Non-Ischemic CRVO, Ischemic CRVO_x000D_

2) By Branch Retinal Vein Occlusion (BRVO): Non-Ischemic BRVO, Ischemic BRVO_x000D_

_x000D_

#What Are the Latest Trends in the Retinal Vein Occlusion Treatment Market?#_x000D_

The primary players in the retinal vein occlusion treatment market are concentrating on the development of innovative products like interchangeable biosimilars to improve treatment choices and accessibility for patients. Interchangeable biosimilars are biologic drugs that closely resemble a pre-existing reference biologic, proving effective in managing inflammation and fluid leakage. In an illustration of this, Biocon Biologics Limited, a biosimilar manufacturing firm based in India, obtained approval from the US Food and Drug Administration in May 2024 for their product, Yesafili (aflibercept-jbvf). This product is an interchangeable biosimilar of EYLEA (aflibercept) and acts as a vascular endothelial growth factor (VEGF) inhibitor. It is used to treat various eye-related conditions such as neovascular age-related macular degeneration (wet AMD), macular edema secondary to retinal vein occlusion (branch RVO or central RVO), diabetic macular edema (DME), and myopic choroidal neovascularization (myopic CNV)._x000D_

_x000D_

#Access The Full Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/report/retinal-vein-occlusion-treatment-global-market-report_x000D_

_x000D_

#What Are the Key Regional Markets in the Retinal Vein Occlusion Treatment Industry?#_x000D_

North America was the largest region in the retinal vein occlusion treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the retinal vein occlusion treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Purchase The Full Report Today:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18453_x000D_

_x000D_

#This Report Delivers Insight On: #_x000D_

1. How big is the retinal vein occlusion treatment market, and how is it changing globally?_x000D_

2. Who are the major companies in the retinal vein occlusion treatment market, and how are they performing?_x000D_

3. What are the key opportunities and risks in the retinal vein occlusion treatment market right now?_x000D_

4. Which products or customer segments are growing the most in the retinal vein occlusion treatment market?_x000D_

5. What factors are helping or slowing down the growth of the retinal vein occlusion treatment market?_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 2071930708_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the retinal vein occlusion treatment industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What Is the Current and Projected Market Size of the Retinal Vein Occlusion Treatment Market Through 2034?

In recent times, there has been substantial growth in the market for treatments of retinal vein occlusion. The market value is projected to increase from $2.26 billion in 2024 to $2.43 billion the following year, representing a Compound Annual Growth Rate (CAGR) of 7.3%. Factors contributing to growth during this historical period include the utilization of combined therapies that address multiple aspects of disease pathophysiology, the increasing incidences of diabetes and hypertension, an increase in access to healthcare and specialized retinal care services, the demonstration of the effectiveness of new treatment methods through clinical trials, and progress in anti-VEGF therapies.

It’s predicted that the market size for retinal vein occlusion treatments will experience substantial growth in the imminent years, escalating to a value of $3.18 billion by 2029, with a compound annual growth rate (CAGR) of 7.0%. The anticipated growth throughout the forecast period can be credited to various factors including affordable pricing and favourable reimbursement policies, the patient’s inclination for non-invasive procedures, increased international health expenditure, a surge in the elderly population, and the emergence of innovative drugs and treatments. Noteworthy trends during the projection period encompass advancements in gene therapy, the advent of nanotechnology in drug administration, the application of artificial intelligence (AI) in diagnostic processes, telemedicine and remote patient monitoring, along with the creation of new patient-centered technologies.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18453&type=smp

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Retinal Vein Occlusion Treatment Market?

The escalating frequency of eye-related disorders and diseases is projected to drive the expansion of the retinal vein occlusion treatment market. Eye conditions can encompass anything from minor issues and infections to severe conditions like glaucoma, cataracts, macular degeneration, and diabetic retinopathy. An increase in the occurrence of these conditions is often tied to aging demographics, as well as a rising number of diabetes and hypertension cases. Retinal vein occlusion treatments are designed to stimulate blood circulation, diminish inflammation and avert vision loss, in addition to tackling complications arising from these eye conditions. For instance, in January 2024, the Centers for Disease Control and Prevention reported that more than 3.4 million Americans aged 40 years and older were experiencing blindness or vision impairment. They predict that this number will be two times higher by 2030. Therefore, the rise in eye conditions is fueling the growth of the retinal vein occlusion treatment market.

Which Primary Segments of the Retinal Vein Occlusion Treatment Market Are Driving Growth and Industry Transformations?

The retinal vein occlusion treatment market covered in this report is segmented –

1) By Disease Type: Central Retinal Vein Occlusion (CRVO), Branch Retinal Vein Occlusion (BRVO)

2) By Diagnosis: Optical Coherence Tomography, Fundoscopic Examination, Fluorescein Angiography

3) By Treatment: Anti-Vascular Endothelial Growth Factor (Anti-VEGF), Corticosteroid Drugs, Other Treatments

4) By End-User: Hospital And Clinics, Research And Academics, Other End-Users

Subsegments:

1) By Central Retinal Vein Occlusion (CRVO): Non-Ischemic CRVO, Ischemic CRVO

2) By Branch Retinal Vein Occlusion (BRVO): Non-Ischemic BRVO, Ischemic BRVO

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=18453&type=smp

Which Areas Are Leading Regions in the Retinal Vein Occlusion Treatment Market Expansion Across the Globe?

North America was the largest region in the retinal vein occlusion treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the retinal vein occlusion treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Trends Are Shaping the Future of the Retinal Vein Occlusion Treatment Market?

Leading corporations in the retinal vein occlusion treatment market are focusing on the creation of novel products, like interchangeable biosimilars which are predicted to augment treatment choices and enhance patient accessibility. These interchangeable biosimilars are biological medicines highly similar to the existing reference biologic and can effectively control inflammation and fluid leakage. For example, in May 2024, Biocon Biologics Limited, a biosimilar production firm based in India, secured approval from the US Food and Drug Administration for Yesafili (aflibercept-jbvf); a biosimilar of EYLEA (aflibercept) that can be substituted. It serves as a vascular endothelial growth factor (VEGF) inhibitor and addresses various ophthalmic conditions such as neovascular age-related macular degeneration (wet AMD), macular edema stemming from retinal vein occlusion (central RVO or branch RVO), diabetic macular edema (DME), and myopic choroidal neovascularization (myopic CNV).

View the full report here:

https://www.thebusinessresearchcompany.com/report/retinal-vein-occlusion-treatment-global-market-report

What Parameters Are Used to Define the Retinal Vein Occlusion Treatment Market?

Retinal vein occlusion (RVO) treatment involves various strategies aimed at managing complications caused by blocked blood vessels in the retina. These treatments typically focus on reducing swelling (edema) and preventing further vision loss.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18453

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Retinal Vein Occlusion Treatment Market?

The increasing prevalence of eye conditions is driving the growth of the retinal vein occlusion treatment market, due to aging populations and rising rates of diabetes and hypertension. For example, in January 2024, the Centers for Disease Control and Prevention reported that over 3.4 million Americans aged 40 and older were blind or visually impaired, with this number expected to double by 2030.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18453&type=smp

#What Growth Opportunities Will Drive the Retinal Vein Occlusion Treatment Market’s CAGR Through 2034?

The retinal vein occlusion treatment market size will grow from $2.26 billion in 2024 to $2.43 billion in 2025, at a CAGR of 7.3%. The growth is attributed to the adoption of combination therapies targeting multiple aspects of the disease, the growing prevalence of diabetes and hypertension, expanded healthcare access, clinical trials for new treatments, and the development of anti-VEGF therapies.

The retinal vein occlusion treatment market is projected to reach $3.18 billion by 2029, at a CAGR of 7.0%. Growth is driven by cost-effectiveness, non-invasive treatment preferences, increased healthcare spending, an aging population, and new drug developments. Trends include advancements in gene therapy, nanotechnology for drug delivery, AI in diagnostics, telemedicine, and patient-centric technologies.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18453

What Are the Key Market Innovations in theRetinal Vein Occlusion Treatment Market Over the Coming Years?

Major companies in the retinal vein occlusion treatment market are developing interchangeable biosimilars to enhance treatment options. In May 2024, Biocon Biologics in India received FDA approval for Yesafili, a biosimilar to EYLEA, used to treat various ophthalmic conditions such as retinal vein occlusion and age-related macular degeneration.

Who Are the Top Companies Driving Innovation and Growth in theRetinal Vein Occlusion Treatment Market?

Major companies operating in the retinal vein occlusion treatment market are Roche Holding AG, Bayer AG, Novartis International AG, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Santen Pharmaceutical Co. Ltd., Chengdu Kanghong Pharmaceutical Group Co. Ltd., Spark Therapeutics Inc., Genentech Inc., Apellis Pharmaceuticals Inc., Alimera Sciences Inc., Ocular Therapeutix Inc., EyePoint Pharmaceuticals Inc., Aerpio Pharmaceuticals Inc., REGENXBIO Inc., Stealth BioTherapeutics Corp., Adverum Biotechnologies Inc., Graybug Vision Inc., Oxurion NV, PanOptica Inc., Clearside Biomedical Inc.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/retinal-vein-occlusion-treatment-global-market-report

Which Key Market Segments Comprise the Retinal Vein Occlusion Treatment Market and Drive Its Revenue Growth?

The retinal vein occlusion treatment market covered in this report is segmented –

1) By Disease Type: Central Retinal Vein Occlusion (CRVO), Branch Retinal Vein Occlusion (BRVO)

2) By Diagnosis: Optical Coherence Tomography, Fundoscopic Examination, Fluorescein Angiography

3) By Treatment: Anti-Vascular Endothelial Growth Factor (Anti-VEGF), Corticosteroid Drugs, Other Treatments

4) By End-User: Hospital And Clinics, Research And Academics, Other End-Users

Subsegments:

1) By Central Retinal Vein Occlusion (CRVO): Non-Ischemic CRVO, Ischemic CRVO

2) By Branch Retinal Vein Occlusion (BRVO): Non-Ischemic BRVO, Ischemic BRVO

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=18453&type=smp

Which Regions Are Emerging as Leaders in the Retinal Vein Occlusion Treatment Market?

North America was the largest region in the retinal vein occlusion treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the retinal vein occlusion treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Retinal Vein Occlusion Treatment Market 2025, By The Business Research Company:

Ophthalmic Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/ophthalmic-drugs-global-market-report

Ophthalmic Viscoelastic Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/ophthalmic-viscoelastic-devices-global-market-report

Ophthalmic Lasers Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/ophthalmic-lasers-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

What fueled the previous growth in the retinal vein occlusion treatment market?

In recent times, the industry for retinal vein occlusion treatment has seen impressive growth. The market, valued at $2.26 billion in 2024, is predicted to increase to $2.43 billion in 2025, showcasing a compound annual growth rate (CAGR) of 7.3%. This robust expansion in the historical timeframe is credited to various factors notably, the integration of combination therapies that address multiple elements of disease pathophysiology, a rise in diabetes and hypertension cases, broader accessibility to healthcare amenities and specialized retinal treatment. This is compounded by the success of clinical trials that underline the effectiveness of new treatment approaches and the maturation of anti-VEGF treatments.

What will be the retinal vein occlusion treatment market size in the future?

The retinal vein occlusion treatment market size is expected to see strong growth in the next few years. It will grow to $3.18 billion in 2029 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to cost-effectiveness and reimbursement policies, patient preferences for non-invasive treatments, increased healthcare spending globally, an increasing aging population, and the development of new drugs and therapies. Major trends in the forecast period include gene therapy advancements, nanotechnology for drug delivery, artificial intelligence (AI) in diagnostics, telemedicine and remote monitoring, and the development of patient-centric technologies.

Get your retinal vein occlusion treatment market report here!

https://www.thebusinessresearchcompany.com/report/retinal-vein-occlusion-treatment-global-market-report

What main drivers are fueling expansion in the retinal vein occlusion treatment market?

The escalating numbers of eye conditions globally are projected to fuel the expansion of the retinal vein occlusion treatment market in future. Eye conditions encompass all types of disorders or diseases impacting the eyes or vision, extending from minor issues and infections to critical conditions such as glaucoma, cataracts, macular degeneration, and diabetic retinopathy. The increasing instances of eye conditions are credited to factors like the ageing population and the rising prevalence of diabetes and hypertension. The treatment of retinal vein occlusion focuses on restoring blood flow and minimizing inflammation to avoid loss of vision and manage complications related to this eye condition. As an example, the Centers for Disease Control and Prevention reported in January 2024 that more than 3.4 million Americans aged 40 years and above were afflicted by blindness or vision impairment, a figure expected to double by 2030. Hence, the escalating prevalence of eye conditions is accelerating the growth of the retinal vein occlusion treatment market.

What key areas define the segmentation of the global retinal vein occlusion treatment market?

The retinal vein occlusion treatment market covered in this report is segmented –

1) By Disease Type: Central Retinal Vein Occlusion (CRVO), Branch Retinal Vein Occlusion (BRVO)

2) By Diagnosis: Optical Coherence Tomography, Fundoscopic Examination, Fluorescein Angiography

3) By Treatment: Anti-Vascular Endothelial Growth Factor (Anti-VEGF), Corticosteroid Drugs, Other Treatments

4) By End-User: Hospital And Clinics, Research And Academics, Other End-Users

Subsegments:

1) By Central Retinal Vein Occlusion (CRVO): Non-Ischemic CRVO, Ischemic CRVO

2) By Branch Retinal Vein Occlusion (BRVO): Non-Ischemic BRVO, Ischemic BRVO

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18453&type=smp

Who are the key firms paving the way for growth in the retinal vein occlusion treatment market?

Major companies operating in the retinal vein occlusion treatment market are Roche Holding AG, Bayer AG, Novartis International AG, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Santen Pharmaceutical Co. Ltd., Chengdu Kanghong Pharmaceutical Group Co. Ltd., Spark Therapeutics Inc., Genentech Inc., Apellis Pharmaceuticals Inc., Alimera Sciences Inc., Ocular Therapeutix Inc., EyePoint Pharmaceuticals Inc., Aerpio Pharmaceuticals Inc., REGENXBIO Inc., Stealth BioTherapeutics Corp., Adverum Biotechnologies Inc., Graybug Vision Inc., Oxurion NV, PanOptica Inc., Clearside Biomedical Inc.

Which trends are expected to transform the retinal vein occlusion treatment market?

Leading corporations in the retinal vein occlusion treatment market are concentrating on the development of innovative solutions, including interchangeable biosimilars, to better diverse therapy options and increase accessibility for patients. An interchangeable biosimilar is a biological drug closely similar to a pre-existing reference biologic and is deemed an effective alternative to control inflammation and fluid leakage. For example, in May 2024, Indian-based biosimilar production company, Biocon Biologics Limited, won approval from the US Food and Drug Administration for Yesafili (aflibercept-jbvf), a biosimilar interchangeable to EYLEA (aflibercept). It serves as a vascular endothelial growth factor (VEGF) inhibitor, tackling a variety of eye-related conditions such as neovascular age-related macular degeneration (wet AMD), macular edema resultant from retinal vein occlusion (branch RVO or central RVO), diabetic macular edema (DME), and myopic choroidal neovascularization (myopic CNV).

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18453

What regions are contributing significantly to the growth of the retinal vein occlusion treatment market?

North America was the largest region in the retinal vein occlusion treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the retinal vein occlusion treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Ophthalmic Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/ophthalmic-drugs-global-market-report

Ophthalmic Viscoelastic Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/ophthalmic-viscoelastic-devices-global-market-report

Ophthalmic Lasers Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/ophthalmic-lasers-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: